It is not a mistake if you take PRR as R/D center for ovarian cancer drug and if DNDN could be successful, you could not say it is impossible that DNDN would leave PRR alone and become a powerful competitor in the immune vaccine therapy market.
It is not true "PRR had proved nothing yet!" Have you read its announcements since its Phase I trials? Do you think the PRR board is crazy and try to commercialize something which is not exist?
It is understandable if you wonder but should wonder logically and know the Known and the UnKnown, which would help you to make a correct mind and decision.
It is not a mistake if you take PRR as R/D center for ovarian...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 286261 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 253490 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |